ImmunityBio, Inc. 8-K

What Happened
ImmunityBio, Inc. announced on January 15, 2026 (Form 8-K Item 2.02) that it issued a press release with preliminary, unaudited financial results for the fiscal quarter and full year ended December 31, 2025. The company stated these figures are preliminary estimates based on information available as of the press release date and are not a complete statement of its financial position or operating results.

Key Details

• The press release was issued January 15, 2026 and is furnished as Exhibit 99.1 to the 8-K.
• The results disclosed are preliminary and unaudited, based solely on information available as of the press release date.
• Final audited numbers will be reported in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and may be subject to adjustments.
• The company explicitly warned these preliminary estimates may differ materially from the amounts that will appear in the completed consolidated financial statements.

Why It Matters
Investors should treat the announced figures as provisional. Because the results are preliminary and subject to the company’s financial close procedures and audit adjustments, the final revenue, earnings and other metrics in the upcoming Form 10-K could change materially. Use the press release for a timely view of company performance, but rely on the audited 10-K for finalized, definitive financial data when making investment decisions.